title: Emerging drugs for nosocomial pneumonia.
abstract: BACKGROUND
  Hospital-acquired pneumonia (HAP) is one of the leading nosocomial infections worldwide and is associated with an elevated morbidity and mortality and increased hospital costs. Nevertheless, prompt and adequate antimicrobial treatment is mandatory following VAP development, especially in the face of multidrug resistant pathogens.
  
  
  METHODS
  We searched Pubmed and ClinicalTrials.gov site reports in English language of phase III clinical trials, between 2000-2016 referring to the antibiotic treatment of nosocomial pneumonia. We provide a summary of latest approved drugs for HAP and emerging drugs with potential indication nosocomial pneumonia.
  
  
  CONCLUSIONS
  There are several promising compounds on their way, as tedizolid-a new oxazolidone, iclaprim-a novel drug, related to trimethoprim, plazomicin-a new aminoglycoside and two combinations of ceftazidime/avibactam and ceftolozane/tazobactam against MDR bacteria, especially against MRSA and Gram-negative ESBL bacteria.
authors.affiliation: a 6th Respiratory Department , Sotiria Chest Diseases Hospital , Athens , Greece.
authors.forename: Adamantia
authors.initials: A
authors.lastname: Liapikou
authors.affiliation: b Department of Pneumology, Institut Clinic del Tórax, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigaciones biomedicas En Red-Enfermedades Respiratorias (CibeRes CB06/06/0028)-ISCIII, Hospital Clinic , University of Barcelona , Barcelona , Spain.
authors.forename: Antoni
authors.initials: A
authors.lastname: Torres
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D017277:Drug Approval; D015195:Drug Design; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents
keywords: Nosocomial pneumonia; antibiotics; ceftazidime+avibactam; ceftobiprole; emerging; plazomicin